Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA sells biosimilars business to Fresenius for up to €670mm

Executive Summary

Merck KGAA divested its biosimilars business to Fresenius Kabi AG for total consideration of up to €670mm ($706.2mm). The price includes €170mm up front plus up to €500mm in development-based earn-outs. Fresenius will also pay single-digit royalties on future product sales.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture/Spin-Out
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies